UBS Group’s KALA BIO KALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.7K | Buy |
9,057
+7,720
| +577% | +$37.5K | ﹤0.01% | 8306 |
|
|
2026
Q1 | $11.6K | Buy |
1,337
+859
| +180% | +$18.2K | ﹤0.01% | 8293 |
|
|
2025
Q4 | $13.3K | Buy |
478
+314
| +191% | +$14.1K | ﹤0.01% | 8060 |
|
|
2025
Q3 | $12.5K | Buy |
164
+163
| +16,300% | +$80.8K | ﹤0.01% | 8432 |
|
|
2025
Q2 | $162 | Sell |
1
-67
| -99% | -$13.1K | ﹤0.01% | 9951 |
|
|
2025
Q1 | $19.6K | Buy |
68
+5
| +8% | +$1.89K | ﹤0.01% | 8255 |
|
|
2024
Q4 | $21.9K | Buy |
63
+62
| +6,200% | +$19.5K | ﹤0.01% | 7812 |
|
|
2024
Q3 | $193 | Hold |
1
| – | – | ﹤0.01% | 9082 |
|
|
2024
Q2 | $241 | Sell |
1
-43
| -98% | -$14.2K | ﹤0.01% | 9044 |
|
|
2024
Q1 | $17.3K | Buy |
44
+30
| +214% | +$11.1K | ﹤0.01% | 6989 |
|
|
2023
Q4 | $4.87K | Buy |
14
+11
| +367% | +$3.89K | ﹤0.01% | 7817 |
|
|
2023
Q3 | $1.29K | Buy |
+3
| New | +$1.97K | ﹤0.01% | 7998 |
|
|
2023
Q2 | – | Sell |
-38
| Closed | -$29.5K | – | 8309 |
|
|
2023
Q1 | $28.9K | Buy |
38
+32
| +533% | +$27.9K | ﹤0.01% | 6828 |
|
|
2022
Q4 | $11.8K | Sell |
6
-23
| -79% | -$9.11K | ﹤0.01% | 8351 |
|
|
2022
Q3 | $15K | Buy |
29
+4
| +16% | +$3.14K | ﹤0.01% | 7806 |
|
|
2022
Q2 | $19K | Buy |
25
+18
| +257% | +$28.2K | ﹤0.01% | 6942 |
|
|
2022
Q1 | $25K | Sell |
7
-7
| -50% | -$18.3K | ﹤0.01% | 7193 |
|
|
2021
Q4 | $42K | Buy |
14
+10
| +250% | +$46.4K | ﹤0.01% | 7069 |
|
|
2021
Q3 | $25K | Sell |
4
-134
| -97% | -$1.16M | ﹤0.01% | 6920 |
|
|
2021
Q2 | $1.83M | Buy |
138
+115
| +500% | +$1.81M | ﹤0.01% | 3652 |
|
|
2021
Q1 | $386K | Buy |
23
+21
| +1,050% | +$410K | ﹤0.01% | 5058 |
|
|
2020
Q4 | $40K | Buy |
2
+1
| +100% | +$18.8K | ﹤0.01% | 6383 |
|
|
2020
Q3 | $18K | Sell |
1
-4
| -80% | -$91.9K | ﹤0.01% | 6392 |
|
|
2020
Q2 | $144K | Sell |
5
-2
| -29% | -$56.7K | ﹤0.01% | 5037 |
|
|
2020
Q1 | $145K | Sell |
7
-6
| -46% | -$95.9K | ﹤0.01% | 4971 |
|
|
2019
Q4 | $119K | Buy |
13
+7
| +117% | +$67.6K | ﹤0.01% | 5912 |
|
|
2019
Q3 | $53K | Buy |
6
+4
| +200% | +$48.7K | ﹤0.01% | 6165 |
|
|
2019
Q2 | $31K | Buy |
2
+1
| +100% | +$16.6K | ﹤0.01% | 6306 |
|
|
2019
Q1 | $16K | Sell |
1
-1
| -50% | -$17.8K | ﹤0.01% | 6487 |
|
|
2018
Q4 | $19K | Buy |
+2
| New | +$34.7K | ﹤0.01% | 6829 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7493 |
|
|
2018
Q2 | – | Sell |
-1
| Closed | -$38.4K | – | 7335 |
|
|
2018
Q1 | $21K | Buy |
+1
| New | +$38K | ﹤0.01% | 6380 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | -$54K | – | 7974 |
|
|
2017
Q3 | $54K | Buy |
+1
| New | +$54.9K | ﹤0.01% | 5740 |
|
Other funds holding KALA
TRCT
UBS Group's KALA Position: Q2 2026 in Review
UBS Group increased its KALA BIO (KALA) stake by 577% in Q2 2026, buying an estimated $37.5K and bringing the position to 9,057 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #8306.
UBS Group first reported a position in KALA in Q3 2017 and has held it in 32 quarters since. The position peaked at $1.83M in Q2 2021. 14 funds tracked by Wall St. Rank hold KALA as of Q2 2026.
- UBS Group held 9,057 shares of KALA BIO worth $15.7K as of Q2 2026.
- UBS Group bought 7,720 KALA BIO shares in Q2 2026, an estimated $37.5K.
- KALA BIO made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8306 holding.
- UBS Group first reported a position in KALA BIO in Q3 2017 and has held it in 32 quarters since.
- UBS Group's KALA BIO position peaked at $1.83M in Q2 2021.
- 14 funds tracked by Wall St. Rank held KALA BIO as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.